Royal Unibrew A/S (RBREW)
Copenhagen Exchange · Denmark · prices in DKK · close of 23 Oct 2026
Key indicators
| Last close | DKK 433.80 |
|---|---|
| 52-week range | 394.00 – 653.50 |
| Return, 1 month / 3 months | +4.1% / −6.7% |
| Return, 1 year / 3 years | −10.6% / −7.4% |
| Trend | Below its 200-day average |
| RSI (14) | 60 |
| Volatility (1 year) | 36.5% |
| Worst drawdown (1 year) | -38.5% |
| Average daily value traded | 59.09M DKK |
| Dividend yield | 3.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Royal Unibrew is a Danish beverage company based in Denmark that brews and markets beer under brands such as Faxe, Ceres, Albani and Odense. It also makes soft drinks, malt beverages, cider and bottled water. Its customers are retailers, wholesalers, bars and restaurants, and consumers in Denmark, other Nordic countries, the Baltic states and selected export markets. The company combines local brewery traditions with a broad drinks portfolio.
The shares are listed on the Copenhagen Exchange in Denmark under the code RBREW, and the price on this page is in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Royal Unibrew A/S (RBREW) trades on the Copenhagen Exchange in Denmark. It last closed at DKK 433.80 on 23 October 2026.
Its price-based Market X-Ray is 42 out of 100 (a weak price profile), ranking 112 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.6% and over the last three months it fell 6.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Copenhagen Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 18 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -9.3% | ||
| From 52-week high | -33.3% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.7% | ||
| 6-month return | 10.2% | ||
| 12-month return, skipping the last month | -14.1% | ||
| Stability (higher is calmer) | 33 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.5% | ||
| Liquidity | 87 · Strong | Trades actively. | |
| Average daily value traded | 59.09M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | 66 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.7% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | +4.1% |
| 3 months | −6.7% |
| 6 months | +10.2% |
| 1 year | −10.6% |
| 3 years | −7.4% |
| 5 years | −37.0% |
Signals
| 50-day / 200-day average | 421.80 / 478.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 8.01 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Apr 2026 | DKK 16.0000 |
| 30 Apr 2025 | DKK 15.0000 |
| 1 Oct 2024 | DKK 14.5000 |
| 28 Apr 2023 | DKK 14.5000 |
| 29 Apr 2022 | DKK 14.5000 |
| 29 Apr 2021 | DKK 13.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Copenhagen Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.